Trusted News Discovery Since 2008
{{/content}}
Biocon Biologics settles with Janssen; paves way for launch of biosimilar in US
Credit: IndiaTimes- Published on February 29, 2024
Biocon Biologics signs settlement and license agreement with Janssen Biotech and Johnson & Johnson to commercialize Bmab 1200, a biosimilar to Stelara, in the US once approved by the USFDA. The therapy is expected to launch in February 2025.